Spyre Therapeutics OverviewSpyre Therapeutics EBIT
EBIT (Earnings Before Interest and Taxes) analysis for SYRE.
Quarterly EBIT
-$45.64M
↑ 14.8% YoY
As of Mar 31, 2026
Annual EBIT (TTM)
-$196.42M
↑ 8.37% YoY
Trailing 12 months ending Mar 31, 2026
Spyre Therapeutics OverviewEBIT (Earnings Before Interest and Taxes) analysis for SYRE.
As of Mar 31, 2026
Trailing 12 months ending Mar 31, 2026